Ocular Therapeutix has become a single-asset NDA story wearing a small commercial jacket. The jacket is DEXTENZA, a dexamethasone canalicular insert whose net sales have stopped growing because reimbursement, not unit demand, now sets the ceiling. The real equity is AXPAXLI, an axitinib hydrogel implant aimed at wet age-related macular degeneration. A February superiority readout versus on-label aflibercept, a May Type C alignment, and a mid-September pre-NDA meeting have turned that asset from a two-trial hope into a single-trial filing plan. The share last changed hands near $10.
The print underneath that clock is not the thesis. Second-quarter product revenue was flat at $13 million, which tells the reader that the legacy insert is a cash trickle rather than a growth engine. Operating cash use in the first half reached $133 million as the company ran four retina studies and started building a launch organization. Cash still stood at $599 million at mid-year, enough on management's stated plan to carry operations into twenty twenty-eight, but that plan explicitly leaves out a full AXPAXLI launch budget. The tension is simple: the regulatory path is clearer than it was in winter, and the spending path is already accelerating.
The second-quarter operating loss reached $82 million because selling and administrative costs rose as the company hired ahead of a possible twenty twenty-seven launch, not because the science reversed. Research spending stayed elevated as the superiority study closed and the repeat-dose and diabetic programs continued. What the next several months resolve is whether the agency accepts a package built on one successful superiority trial plus interim safety, and whether payers treat a durability claim as worth a premium over Eylea and Vabysmo. If the filing lands clean and the label carries superiority language, the equity is a launch-prep story. If the agency demands more efficacy from the still-blinded repeat-dose study, the clock stretches and the cash cushion starts to look thinner.